Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · IEX Real-Time Price · USD
22.12
+0.25 (1.14%)
At close: Apr 26, 2024, 4:00 PM
21.75
-0.37 (-1.67%)
After-hours: Apr 26, 2024, 7:22 PM EDT
Arrowhead Pharmaceuticals Revenue
Arrowhead Pharmaceuticals had revenue of $181.74M in the twelve months ending December 31, 2023, down -34.71% year-over-year. Revenue in the quarter ending December 31, 2023 was $3.55M, a -94.32% decrease year-over-year. In the fiscal year ending September 30, 2023, Arrowhead Pharmaceuticals had annual revenue of $240.74M, a decrease of -1.03%.
Revenue (ttm)
$181.74M
Revenue Growth
-34.71%
P/S Ratio
15.08
Revenue / Employee
$346,171
Employees
525
Market Cap
2.74B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Sep 30, 2023 | 240.74M | -2.50M | -1.03% |
Sep 30, 2022 | 243.23M | 104.94M | 75.89% |
Sep 30, 2021 | 138.29M | 50.30M | 57.16% |
Sep 30, 2020 | 87.99M | -80.80M | -47.87% |
Sep 30, 2019 | 168.80M | 152.65M | 945.67% |
Sep 30, 2018 | 16.14M | -15.27M | -48.60% |
Sep 30, 2017 | 31.41M | 31.25M | 19,736.49% |
Sep 30, 2016 | 158.33K | -223.67K | -58.55% |
Sep 30, 2015 | 382.00K | 207.00K | 118.29% |
Sep 30, 2014 | 175.00K | -115.27K | -39.71% |
Sep 30, 2013 | 290.27K | 143.39K | 97.63% |
Sep 30, 2012 | 146.88K | -149.26K | -50.40% |
Sep 30, 2011 | 296.14K | - | - |
Sep 30, 2010 | 0 | - | - |
Sep 30, 2009 | 3.76M | 2.45M | 188.38% |
Sep 30, 2008 | 1.30M | 95.18K | 7.88% |
Sep 30, 2007 | 1.21M | 746.74K | 161.88% |
Sep 30, 2006 | 461.28K | -129.40K | -21.91% |
Sep 30, 2005 | 590.68K | 394.38K | 200.90% |
Sep 30, 2004 | 196.31K | - | - |
Sep 30, 2003 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 8.76B |
Amedisys | 2.24B |
LivaNova | 1.15B |
Azenta | 641.02M |
Immunocore Holdings | 249.43M |
TransMedics Group | 241.62M |
Arcellx | 110.32M |
IDEAYA Biosciences | 23.39M |
ARWR News
- 19 hours ago - Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars - Business Wire
- 2 days ago - Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results - Business Wire
- 2 days ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease - Business Wire
- 19 days ago - Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo - Business Wire
- 25 days ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy - Business Wire
- 7 weeks ago - Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences - Business Wire